Vaccine against SARS-CoV-2 based on non-infectious replicons

Study on the development of a prototype vaccine against SARS-CoV-2 that can be administered intranasally in a single dose


Interview with Sonia Zúñiga, virologist and researcher at Centro Nacional de Biotecnología del Centro Superior de Investigaciones Científicas (CSIC) about this study. Source: ConSalud.es

Description of the Study:

  • Title: Desarrollo de una vacuna contra el SARS-CoV-2 basada en replicones no infectivos.
  • Principal Investigators: Luis Enjuanes, Isabel Sola y Sonia Zuñiga.
  • Centers of Implementation: Consejo Superior de Investigaciones Científicas (CSIC). 
  • Study Population: Trials with mice and hamsters are forthcoming.
  • Study type: Study based on laboratory research. Clinical trial coming soon.
  • Design: Defined RNA replicon, which multiplies the gene dose that triggers protection but complementary technologies are needed for vaccine delivery.

Objectives of the Study:

Principal Objective: To generate SARS-CoV-2 virus in the laboratory by assembling synthetic DNA fragments and to eliminate from its genome the genes responsible for virulence using reverse genetics techniques to introduce attenuating mutations and obtain non-infectious and highly immunogenic derivatives as vaccine candidates against SARS-CoV-2.

Secondary objective: Development of animal models (transgenic mice) for the validation of vaccines and other therapeutic agents against COVID-19.

More about this Study:

It is an original vaccine based on the genetic manipulation of SARS-CoV-2 itself, from which we have derived an RNA replicon that multiplies the gene dose that triggers protection. This vaccine includes mutations of the UK, South African and Brazilian viruses, and probably also of a US variant that has appeared in California and New York.

It is also self-amplifying, which means that the dose of RNA injected can multiply 5,000 times inside the body. It also generates a sterilizing immunity, i.e. vaccinated people not only do not get sick, but also do not become infected and do not transmit the virus.

On the other hand, administration could be intranasal. The mucous membranes (nasal, ocular, respiratory, etc.) are spaces open to the exterior and immunity in these areas is best induced locally, presenting the antigen there. This virus enters our body primarily through the respiratory tract.

Unnamed 3

Other Studies:

Un bain de bouche antiviral et COVID-19

L’utilisation d’un bain de bouche contenant de la β-cyclodextrine et du citrox (bioflavonoïdes) (CDCM), disponible en pharmacie, permet de réduire la charge virale du SRAS-CoV-2 dans la salive.

Influence du sexe sur les anticorps neutralisants contre le SARS-CoV-2

Cette étude vise à déterminer les différences dans l’évolution de la réponse immunitaire dans les mois qui suivent l’infection par le SARS-CoV-2 chez les hommes et les femmes.

Diagnose

COVIDAir : une nouvelle technologie pour détecter les patients COVID-19

Cette étude vise à déterminer la validité d’une nouvelle méthode de détection du COVID-19 par la caractérisation des molécules présentes dans l’air expiré.

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la progestérone dans le traitement de COVID-19 chez les hommes hospitalisés.

Flower 729514 1920

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.

CombivacS

Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of Vaxcevria vaccine (AstraZeneca).

Blood Filter for the Treatment of COVID-19

Is removing SARS-CoV-2 from the blood sufficient to decrease the severity of critically ill COVID patients? This clinical trial aims to test the efficacy of a new blood filter for the treatment of COVID-19.

Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer’s COVID vaccine in children under 12 years of age.